Role of modern radiotherapy in managing patients with hepatocellular carcinoma
Autor: | Hon-Yi Lin, Moon-Sing Lee, Shih-Kai Hung, Wen-Yen Chiou, Liang-Cheng Chen |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
medicine.medical_specialty Carcinoma Hepatocellular Hepatocellular carcinoma Combined treatment medicine.medical_treatment Review Guideline Radiosurgery Systemic therapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Modalities Radiotherapy business.industry Liver Neoplasms Gastroenterology General Medicine Immunotherapy Stereotactic body radiotherapies medicine.disease Radiation therapy 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Neoplasm Recurrence Local Primary liver cancer business Stereotactic body radiotherapy |
Zdroj: | World Journal of Gastroenterology |
ISSN: | 1007-9327 |
Popis: | Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Several treatment options are available for managing HCC patients, classified roughly as local, local-regional, and systemic therapies. The high post-monotherapy recurrence rate of HCC urges the need for the use of combined modalities to increase tumor control and patient survival. Different international guidelines offer treatment recommendations based on different points of view and classification systems. Radiotherapy (RT) is a well-known local-regional treatment modality for managing many types of cancers, including HCC. However, only some of these treatment guidelines include RT, and the role of combined modalities is rarely mentioned. Hence, the present study reviewed clinical evidence for the use of different combined modalities in managing HCC, focusing on modern RT's role. Modern RT has an increased utility in managing HCC patients, mainly due to two driving forces. First, technological advancement (e.g., stereotactic body radiotherapy and advanced proton-beam therapy) enables precise delivery of radiation to increase tumor control and reduce side effects in the surrounding normal tissue. Second, the boom in developing target therapies and checkpoint-blockade immunotherapy prolongs overall survival in HCC patients, re-emphasizing the importance of local tumor control. Remarkably, RT combines with systemic therapies to generate the systemic therapy augmented by radiotherapy effect, a benefit now being actively investigated. |
Databáze: | OpenAIRE |
Externí odkaz: |